Filing Flows

Filing Flows › Companies › Core Laboratories › Cash flow

Core Laboratories cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$1.7M in Q3 2026 · $10.4M over twelve months

Operating cash flow$5.0M
Capital spending−$3.2M
Free cash flow+$1.7M
Cash / net income0.9×
Cash conversion cycle95 days

Analysis

In Q3 2026, Core Laboratories generated $5.0M of operating cash flow and spent $3.2M on capital projects, leaving free cash flow of $1.7M. That is $4.8M less than in Q3 2025 ($6.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was $24.7M; the largest uses were capital spending ($14.3M), buybacks ($10.4M), other investing ($3.1M); besides operations, cash came from asset & business sales ($3.8M); the cash balance fell by $4.3M.

Operating cash flow was $5.0M against net income of $5.5M — 0.9× profit, roughly in line with earnings. The largest differences: receivables −$6.8M, accrued liabilities +$4.8M, depreciation & amortization +$3.7M.

Its cash conversion cycle was 95 days (receivables 78 + inventory 52 − payables 35).

Free cash flow

Core Laboratories: free cash flow by quarterCore Laboratories: free cash flow by quarter$17.4MQ4 2024$3.9MQ1 2025$10.4MQ2 2025$6.5MQ3 2025$5.0MQ4 2025$517KQ1 2026$3.1MQ2 2026$1.7MQ3 2026
Operating cash flow less capital spending.
Core Laboratories: operating cash flow against capital spendingCore Laboratories: operating cash flow against capital spendingOperating cash flowCapital spending$20.6M$3.2MQ4 2024$6.7M$2.8MQ1 2025$13.9M$3.5MQ2 2025$8.5M$2.0MQ3 2025$7.9M$2.9MQ4 2025$4.0M$3.4MQ1 2026$7.8M$4.7MQ2 2026$5.0M$3.2MQ3 2026
Latest (Q3 2026): Operating cash flow $5.0M, Capital spending $3.2M.

Capital allocation, year by year

Core Laboratories: where the cash came from (up) and went (down), by fiscal yearCore Laboratories: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksDividendsFY2021: Operating cash flow $36.6MFY2021: Net borrowing −$71.0MFY2021: Shares issued $60.0MFY2021: Asset sales $873KFY2021: Capital spending −$13.5MFY2021: Buybacks −$8.3MFY2021: Dividends −$1.8M$97.5MFY2021FY2022: Operating cash flow $25.0MFY2022: Net borrowing −$15.0MFY2022: Asset sales $240KFY2022: Capital spending −$10.2MFY2022: Buybacks −$3.9MFY2022: Dividends −$1.9M$25.2MFY2022FY2023: Operating cash flow $24.8MFY2023: Net borrowing −$9.0MFY2023: Capital spending −$10.6MFY2023: Buybacks −$2.2MFY2023: Dividends −$1.9M$24.8MFY2023FY2024: Operating cash flow $56.4MFY2024: Net borrowing −$38.0MFY2024: Capital spending −$11.9MFY2024: Buybacks −$5.3MFY2024: Dividends −$1.9M$56.4MFY2024FY2025: Operating cash flow $37.0MFY2025: Net borrowing −$15.0MFY2025: Asset sales $3.0MFY2025: Capital spending −$11.2MFY2025: Acquisitions −$1.2MFY2025: Buybacks −$12.4MFY2025: Dividends −$1.9M$40.0MFY2025
Over these 5 years operating cash flow totalled $180M; the largest uses were net borrowing ($148M) and capital spending ($57.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$21.4M
Debt$115M
Net debt$93.4M

Core Laboratories funds itself: free cash flow was $10.4M over the last twelve months, and $21.4M of cash and investments stands against $115M of debt.

Where the cash came from and went

Core Laboratories: sources (+) and uses (−) of cash, Q3 2026Core Laboratories: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$5.0MCapital spending−$3.2MNet borrowing (+) / repaid (−)−$1.6MCash drawn (+) / kept (−)$1.4MBuybacks−$1.1MDividends−$459KAsset & business sales$70KOther investing−$15KOther financing−$1K
Core Laboratories: sources (+) and uses (−) of cash, TTM to Q3 2026Core Laboratories: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$24.7MCapital spending−$14.3MBuybacks−$10.4MCash drawn (+) / kept (−)$4.3MAsset & business sales$3.8MOther investing−$3.1MNet borrowing (+) / repaid (−)−$2.2MDividends−$1.8MAcquisitions−$620KOther financing−$186K

From profit to cash

Core Laboratories: net income to operating cash flow, Q3 2026Core Laboratories: net income to operating cash flow, Q3 2026Net income$5.5MDepreciation & amortization$3.7MStock-based pay$1.3MGains on disposals−$57KOther non-cash$42KReceivables−$6.8MInventory−$2.9MPayables−$583KAccrued liabilities$4.8MDeferred revenue$768KPrepaid and other assets−$2.6MOther liabilities$21KOperating cash flow$5.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202678523595
Q2 202679523695
Q1 202682503497
Q4 202574473191
Q3 202577523494
Q2 202581523598
Q1 2025835433104
Q4 2024825430106

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksDividendsNet borrowing (+) / repaid (−)Cash drawn (+) / kept (−)Free cash flow
Q3 2026$5.0M−$3.2M—−$1.1M−$459K−$1.6M$1.4M$1.7M
Q2 2026$7.8M−$4.7M—−$2.7M−$460K−$625K$84K$3.1M
Q1 2026$4.0M−$3.4M—−$4.0M−$460K$4.0M−$117K$517K
Q4 2025$7.9M−$2.9M−$620K−$2.7M−$466K−$4.0M$2.9M$5.0M
Q3 2025$8.5M−$2.0M—−$5.0M−$465K−$9.0M$5.6M$6.5M
Q2 2025$13.9M−$3.5M—−$2.7M−$469K—−$9.1M$10.4M
Q1 2025$6.7M−$2.8M—−$2.0M−$469K−$2.0M−$3.0M$3.9M
Q4 2024$20.6M−$3.2M—−$4.9M−$469K−$14.0M$2.3M$17.4M

Core Laboratories: income statement and cash flow

Core Laboratories, Q3 2026: revenue $132M (-2% year over year), operating margin 9.1%. The chart follows the revenue to costs, profit and cash.

Core Laboratories: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.